By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
Mepolizumab targets IL-5 and eosinophils, key players in the pathogenesis of EGPA. Other immunosuppressants are less specific and cause more profound immunosuppression. This probably the main reason mepolizumab took center stage, and the investment in its study in EGPA was justified.